X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TORRENT PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA TORRENT PHARMA AUROBINDO PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 19.8 45.7 43.3% View Chart
P/BV x 3.7 6.2 59.8% View Chart
Dividend Yield % 0.3 0.8 40.9%  

Financials

 AUROBINDO PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
TORRENT PHARMA
Mar-18
AUROBINDO PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8091,550 52.2%   
Low Rs5041,144 44.1%   
Sales per share (Unadj.) Rs281.1354.7 79.2%  
Earnings per share (Unadj.) Rs41.440.1 103.2%  
Cash flow per share (Unadj.) Rs50.964.2 79.2%  
Dividends per share (Unadj.) Rs2.5014.00 17.9%  
Dividend yield (eoy) %0.41.0 36.6%  
Book value per share (Unadj.) Rs199.4273.1 73.0%  
Shares outstanding (eoy) m585.88169.22 346.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.8 61.5%   
Avg P/E ratio x15.933.6 47.2%  
P/CF ratio (eoy) x12.921.0 61.5%  
Price / Book Value ratio x3.34.9 66.8%  
Dividend payout %6.034.9 17.3%   
Avg Mkt Cap Rs m384,630227,897 168.8%   
No. of employees `00017.314.7 117.9%   
Total wages/salary Rs m21,30811,353 187.7%   
Avg. sales/employee Rs Th9,500.74,083.0 232.7%   
Avg. wages/employee Rs Th1,229.4772.3 159.2%   
Avg. net profit/employee Rs Th1,397.9461.3 303.0%   
INCOME DATA
Net Sales Rs m164,66660,021 274.3%  
Other income Rs m1,0202,988 34.1%   
Total revenues Rs m165,68663,009 263.0%   
Gross profit Rs m37,71813,493 279.5%  
Depreciation Rs m5,5804,086 136.6%   
Interest Rs m7773,085 25.2%   
Profit before tax Rs m32,3809,310 347.8%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1832,529 323.6%   
Profit after tax Rs m24,2296,781 357.3%  
Gross profit margin %22.922.5 101.9%  
Effective tax rate %25.327.2 93.0%   
Net profit margin %14.711.3 130.2%  
BALANCE SHEET DATA
Current assets Rs m121,87852,623 231.6%   
Current liabilities Rs m86,80652,022 166.9%   
Net working cap to sales %21.31.0 2,125.3%  
Current ratio x1.41.0 138.8%  
Inventory Days Days130120 108.6%  
Debtors Days Days6876 89.7%  
Net fixed assets Rs m81,03785,016 95.3%   
Share capital Rs m586846 69.2%   
"Free" reserves Rs m116,21845,376 256.1%   
Net worth Rs m116,80446,222 252.7%   
Long term debt Rs m4,51241,115 11.0%   
Total assets Rs m211,052142,432 148.2%  
Interest coverage x42.74.0 1,061.8%   
Debt to equity ratio x00.9 4.3%  
Sales to assets ratio x0.80.4 185.1%   
Return on assets %11.86.9 171.0%  
Return on equity %20.714.7 141.4%  
Return on capital %27.414.2 192.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72714,580 553.7%   
Fx outflow Rs m34,7003,600 963.9%   
Net fx Rs m46,02710,980 419.2%   
CASH FLOW
From Operations Rs m19,5488,942 218.6%  
From Investments Rs m-19,570-47,070 41.6%  
From Financial Activity Rs m8,64234,174 25.3%  
Net Cashflow Rs m8,922-3,655 -244.1%  

Share Holding

Indian Promoters % 54.1 71.5 75.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 7.0 113.2%  
FIIs % 27.7 12.6 219.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.8 115.9%  
Shareholders   69,601 26,511 262.5%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  CADILA HEALTHCARE  ALEMBIC LTD  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 450 Points Down; All Eyes on State Election Results & Urjit Patel's Resignation(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.1% while the Hang Seng is also up 0.1%.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Dec 11, 2018 11:49 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS